Ascendis Pharma A/S
ASND
$223.82
-$3.59-1.58%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 15.36% | 39.24% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 15.36% | 39.24% | |||
| Cost of Revenue | 5.11% | -26.77% | |||
| Gross Profit | 16.55% | 55.64% | |||
| SG&A Expenses | 22.32% | 8.61% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 20.44% | -1.07% | |||
| Operating Income | -78.38% | 121.39% | |||
| Income Before Tax | 53.65% | -68.82% | |||
| Income Tax Expenses | 88.76% | -3.17% | |||
| Earnings from Continuing Operations | 45.21% | -61.69% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 45.21% | -61.69% | |||
| EBIT | -78.38% | 121.39% | |||
| EBITDA | -76.12% | 131.80% | |||
| EPS Basic | 45.44% | -60.90% | |||
| Normalized Basic EPS | 40.88% | -68.01% | |||
| EPS Diluted | 45.44% | -60.90% | |||
| Normalized Diluted EPS | 40.88% | -77.61% | |||
| Average Basic Shares Outstanding | 0.44% | 0.50% | |||
| Average Diluted Shares Outstanding | 0.44% | -4.94% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||